Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators
Clinical Laboratory · 2023
DOI: 10.7754/clin.lab.2022.220442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Laboratory, 2023. Verfasst von Su-Yun Wang und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: We evaluated the JAK2V617F mutation and p-JAK2, SOCS-1, SHP-1 expression in JAK2V617F positive myeloproliferative neoplasms (MPNs) patients and the role of JAK/STAT pathway in human erythroleukemia (HEL) cells, which had JAK2V617F mutation. METHODS: Protein expression of p-JAK2, SOCS-1, SHP-1 in bone marrow biopsies (BMBs) were detected by immunohistochemical staining methods. Cell apoptosis and cell cycle were detected by flow cytometry and Caspase 3/7 assay kits. RESULTS: 1. The p-JAK2, SOCS-1, and SHP-1 expressions were significantly different between JAK2V617F positive MPN and control patients (p < 0.01); 2. After being treated for 3 months, the p-JAK2, SOCS-1, and SHP-1 expressions were significantly different compared with newly diagnosed patients (p < 0.01). 3. HEL cell viabilities were significantly different after being treated with different concentrations of ruxolitinib. Ruxolitinib had a significant effect on the cell apoptosis, viability, and the protein activity of caspase-3 and -7 of HEL cells. 3. The mRNA and protein expressions of JAK2 and the protein expression of p-JAK2 were gradually decreased (p < 0.01, p < 0.05), while the mRNA and protein expressions of SOCS1 and SHP1 were gradually increased (all p < 0.01).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Wang, S. Y., Xie, X. L., Liang, J. Y., & Cheng, Z. Y. (2023). Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2022.220442
Vancouver
Wang SY, Xie XL, Liang JY, Cheng ZY. Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators. Clinical Laboratory. 2023. doi:10.7754/clin.lab.2022.220442
BibTeX
@article{Wang2023,
author = {Wang, Su-Yun and Xie, Xu-Lei and Liang, Jia-Yi and Cheng, Zhi-Yong},
title = {Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators},
journal = {Clinical Laboratory},
year = {2023},
doi = {10.7754/clin.lab.2022.220442}
}
EUVIMED